Ozempic may have revealed the brain’s hidden “craving center”
Research indicates that GLP-1 agonists like Ozempic may reveal a previously hidden 'craving center' in the brain, linking mental imagery to substance overuse disorders. These drugs, originally designed for type 2 diabetes, have shown potential in reducing alcohol and drug consumption, suggesting new avenues for treating obesity and addiction. This understanding could reshape approaches to managing cravings and addictive behaviors.